journal article·2025-09-24Open access

Optimizing Lutein Formulations for Targeted Ocular Drug Delivery: In Vitro and In Vivo Insights

Dao Nguyen, Sampa Sarkar, Thilini Thrimawithana, Terrence Piva, Charlotte E. Conn, Chi Luu, Tien Huynh

ACS Applied Materials & Interfaces· Volume 17· Issue 38

Abstract

Lutein is a plant pigment beneficial for eye health and for preventing retinal-related diseases. However, lutein is unstable, with low oral bioavailability. In this study, lutein from Momordica cochinchinensis was loaded into cubosome lipid nanocarriers, both neutral (lutein-MO) and cationic (lutein-MO-DOTAP); the release, stability, and retinal penetration of the drug were improved. The formulation was biocompatible on retinal cells, showed sustained release in cell culture media and simulated lachrymal fluid, and was stable at 25 °C for 90 days. The cationic formulation, lutein-MO-DOTAP, showed greater uptake into retina cells than unencapsulated lutein and conferred greater protection of retina cells against H 2 O 2 stress. Lutein-MO-DOTAPs enhanced Nrf2 and HO-1 antioxidant genes and downregulated IL-6 inflammatory and VEGF-A angiogenesis genes. Lutein-MO-DOTAPs were detected in mice retina in vivo 1 day post intravitreal injection and 7 days after topical application as eyedrops. We have successfully created a more stable lutein formulation that could penetrate the back of the eye in the retina and be developed as a therapy to enhance eye health or mitigate eye diseases.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Antioxidant Activity and Oxidative Stress · Retinoids in leukemia and cellular processes · Retinal Diseases and Treatments

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Medicine

Deakin University

School of Science

RMIT University

School of Health and Biomedical Sciences

Centre for Eye Research Australia

The Royal Victorian Eye and Ear Hospital

Ophthalmology, Department of Surgery

The University of Melbourne

Funding

RMIT University · State Government of Victoria

References (70)

Show source-provided references
1. 10.1016/j.jff.2023.10559710.1016/j.jff.2023.105597 ↗
2. 10.3390/nu1206172110.3390/nu12061721 ↗
3. 10.12659/msm.90869910.12659/msm.908699 ↗
4. 10.1161/atvbaha.107.15143110.1161/atvbaha.107.151431 ↗
5. 10.26717/bjstr.2018.08.00169310.26717/bjstr.2018.08.001693 ↗
6. 10.1021/acsnano.2c0582410.1021/acsnano.2c05824 ↗
7. 10.1016/j.apmt.2021.10115610.1016/j.apmt.2021.101156 ↗
8. 10.1093/nutrit/nuz09610.1093/nutrit/nuz096 ↗
9. 10.1021/acsbiomaterials.0c0008510.1021/acsbiomaterials.0c00085 ↗
10. 10.1016/j.jcis.2021.02.02710.1016/j.jcis.2021.02.027 ↗
11. 10.1016/j.jcis.2022.04.0310.1016/j.jcis.2022.04.03 ↗
12. 10.2174/221030310866618062915034810.2174/2210303108666180629150348 ↗
13. 10.1021/acsami.0c2095610.1021/acsami.0c20956 ↗
14. 10.1248/cpb.c14-0031810.1248/cpb.c14-00318 ↗
15. 10.1007/s12247-021-09537-610.1007/s12247-021-09537-6 ↗
16. 10.1248/cpb.c14-0031810.1248/cpb.c14-00318 ↗
17. 10.1002/jps.2119010.1002/jps.21190 ↗
18. 10.1107/S002188981302774X10.1107/S002188981302774X ↗
19. 10.1021/ar300285u10.1021/ar300285u ↗
20. Armbruster D. A. · Clin. Biochem. Rev. · 2008 · 29 · 49
21. 10.1016/j.jddst.2019.04.03610.1016/j.jddst.2019.04.036 ↗
22. 10.1155/2024/359409910.1155/2024/3594099 ↗
23. 10.1021/acsomega.9b0114210.1021/acsomega.9b01142 ↗
24. 10.1093/nar/29.9.e4510.1093/nar/29.9.e45 ↗
25. 10.1006/abbi.2000.217110.1006/abbi.2000.2171 ↗
26. 10.1016/j.exer.2017.02.01610.1016/j.exer.2017.02.016 ↗
27. 10.1021/acsbiomaterials.0c0008510.1021/acsbiomaterials.0c00085 ↗
28. 10.3390/pharmaceutics1209079810.3390/pharmaceutics12090798 ↗
29. 10.1016/j.colsurfa.2016.04.03810.1016/j.colsurfa.2016.04.038 ↗
30. 10.3390/ph1603047410.3390/ph16030474 ↗
31. 10.1039/d0ra04971a10.1039/d0ra04971a ↗
32. 10.1080/10408398.2014.97026710.1080/10408398.2014.970267 ↗
33. 10.1016/j.foodhyd.2018.10.00310.1016/j.foodhyd.2018.10.003 ↗
34. 10.1111/ijfs.1339510.1111/ijfs.13395 ↗
35. 10.1016/j.foodres.2017.06.05510.1016/j.foodres.2017.06.055 ↗
36. 10.1016/j.ijbiomac.2020.02.10410.1016/j.ijbiomac.2020.02.104 ↗
37. 10.1371/journal.pone.019251110.1371/journal.pone.0192511 ↗
38. 10.5101/nbe.v1i1.p38-4910.5101/nbe.v1i1.p38-49 ↗
39. 10.1039/c6fd00039h10.1039/c6fd00039h ↗
40. 10.3390/app1011372210.3390/app10113722 ↗
41. 10.15416/ijcp.2015.4.4.28110.15416/ijcp.2015.4.4.281 ↗
42. 10.1371/journal.pone.019141510.1371/journal.pone.0191415 ↗
43. 10.1186/s11671-016-1471-010.1186/s11671-016-1471-0 ↗
44. 10.1016/j.ijpharm.2015.02.01210.1016/j.ijpharm.2015.02.012 ↗
45. 10.1038/s41467-019-12508-810.1038/s41467-019-12508-8 ↗
46. 10.3390/jfb502004310.3390/jfb5020043 ↗
47. 10.1016/j.micron.2006.08.00310.1016/j.micron.2006.08.003 ↗
48. 10.1248/bpb.30.35010.1248/bpb.30.350 ↗
49. 10.1021/acs.jafc.7b0192910.1021/acs.jafc.7b01929 ↗
50. 10.3390/antiox604010010.3390/antiox6040100 ↗
51. 10.1007/s00394-006-0635-610.1007/s00394-006-0635-6 ↗
52. 10.1038/s41419-019-2182-010.1038/s41419-019-2182-0 ↗
53. 10.1016/j.colsurfb.2021.11156410.1016/j.colsurfb.2021.111564 ↗
54. 10.1016/j.biopha.2017.06.09310.1016/j.biopha.2017.06.093 ↗
55. 10.1016/j.xphs.2021.02.00710.1016/j.xphs.2021.02.007 ↗
56. 10.1124/pr.117.01475310.1124/pr.117.014753 ↗
57. 10.1038/s41419-020-02950-810.1038/s41419-020-02950-8 ↗
58. 10.1002/mnfr.20150010910.1002/mnfr.201500109 ↗
59. 10.3389/fphar.2020.0084410.3389/fphar.2020.00844 ↗
60. 10.1016/j.exer.2016.02.01310.1016/j.exer.2016.02.013 ↗
61. 10.1016/j.imbio.2010.05.02510.1016/j.imbio.2010.05.025 ↗
62. Wu W.-C. · Mol. Vis. · 2010 · 16 · 1864
63. 10.1155/2020/790127010.1155/2020/7901270 ↗
64. 10.1016/S1350-9462(02)00043-510.1016/S1350-9462(02)00043-5 ↗
65. 10.1002/advs.20230217410.1002/advs.202302174 ↗
66. 10.1016/j.ophtha.2012.09.00610.1016/j.ophtha.2012.09.006 ↗
67. 10.1097/iae.0b013e3181a94f0110.1097/iae.0b013e3181a94f01 ↗
68. 10.1124/jpet.119.25693310.1124/jpet.119.256933 ↗
69. 10.1186/s12951-023-01992-210.1186/s12951-023-01992-2 ↗
70. 10.1080/17425255.2020.180327810.1080/17425255.2020.1803278 ↗